EP0963441A4 - Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion - Google Patents

Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion

Info

Publication number
EP0963441A4
EP0963441A4 EP97950829A EP97950829A EP0963441A4 EP 0963441 A4 EP0963441 A4 EP 0963441A4 EP 97950829 A EP97950829 A EP 97950829A EP 97950829 A EP97950829 A EP 97950829A EP 0963441 A4 EP0963441 A4 EP 0963441A4
Authority
EP
European Patent Office
Prior art keywords
inactivation
hiv
receptors
therapy
immunodeficiency virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97950829A
Other languages
English (en)
French (fr)
Other versions
EP0963441A1 (de
Inventor
Si-Yi Chen
An-Gang Yang
Xuefan Bai
Ji-Dai Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University
Original Assignee
Wake Forest University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University filed Critical Wake Forest University
Publication of EP0963441A1 publication Critical patent/EP0963441A1/de
Publication of EP0963441A4 publication Critical patent/EP0963441A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97950829A 1996-12-02 1997-12-02 Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion Withdrawn EP0963441A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3227796P 1996-12-02 1996-12-02
US32277P 1996-12-02
PCT/US1997/022198 WO1998024923A1 (en) 1996-12-02 1997-12-02 Inactivation of hiv co-receptors as therapy for hiv infection

Publications (2)

Publication Number Publication Date
EP0963441A1 EP0963441A1 (de) 1999-12-15
EP0963441A4 true EP0963441A4 (de) 2002-10-02

Family

ID=21864069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97950829A Withdrawn EP0963441A4 (de) 1996-12-02 1997-12-02 Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion

Country Status (6)

Country Link
EP (1) EP0963441A4 (de)
JP (1) JP2001505055A (de)
AU (1) AU721121B2 (de)
CA (1) CA2273192A1 (de)
IL (2) IL130160A0 (de)
WO (1) WO1998024923A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013599A1 (en) * 1994-11-01 1996-05-09 Winfried Wels Nucleic acid transfer system
WO1998020135A2 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
WO1998038212A2 (en) * 1997-02-28 1998-09-03 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
WO1998042354A1 (en) * 1997-03-26 1998-10-01 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
WO1999011809A1 (en) * 1997-09-02 1999-03-11 Imperial College Innovations Limited Conjugates that contain the homeodomain of antennapedia
WO1999020759A1 (en) * 1997-10-22 1999-04-29 Genetics Institute, Inc. Chemokines with amino-terminal modifications
WO1999028468A1 (en) * 1997-12-02 1999-06-10 The Regents Of The University Of California Modulating b lymphocyte chemokine/receptor interactions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013599A1 (en) * 1994-11-01 1996-05-09 Winfried Wels Nucleic acid transfer system
WO1998020135A2 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
WO1998038212A2 (en) * 1997-02-28 1998-09-03 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
WO1998042354A1 (en) * 1997-03-26 1998-10-01 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
WO1999011809A1 (en) * 1997-09-02 1999-03-11 Imperial College Innovations Limited Conjugates that contain the homeodomain of antennapedia
WO1999020759A1 (en) * 1997-10-22 1999-04-29 Genetics Institute, Inc. Chemokines with amino-terminal modifications
WO1999028468A1 (en) * 1997-12-02 1999-06-10 The Regents Of The University Of California Modulating b lymphocyte chemokine/receptor interactions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMARA A ET AL: "HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.", THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 7 JUL 1997, vol. 186, no. 1, 7 July 1997 (1997-07-07), 4, pages 139 - 146, XP002203427, ISSN: 0022-1007 *
ARENZANA-SEISDEDOS F ET AL: "HIV blocked by chemokine antagonist.", NATURE. ENGLAND 3 OCT 1996, vol. 383, no. 6599, 3 October 1996 (1996-10-03), 3, pages 400, XP002025860, ISSN: 0028-0836 *
BENKIRANE M ET AL: "Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 5 DEC 1997, vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 30603 - 30606, XP002203429, ISSN: 0021-9258 *
BLEUL C C ET AL: "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.", NATURE. ENGLAND 29 AUG 1996, vol. 382, no. 6594, 29 August 1996 (1996-08-29), pages 829 - 833, XP002028003, ISSN: 0028-0836 *
OBERLIN E ET AL: "The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.", NATURE. ENGLAND 29 AUG 1996, vol. 382, no. 6594, 29 August 1996 (1996-08-29), pages 833 - 835, XP002028004, ISSN: 0028-0836 *
See also references of WO9824923A1 *
SOLARI R ET AL: "Receptor-mediated endocytosis of CC-chemokines.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 APR 1997, vol. 272, no. 15, 11 April 1997 (1997-04-11), pages 9617 - 9620, XP002203428, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
JP2001505055A (ja) 2001-04-17
AU721121B2 (en) 2000-06-22
EP0963441A1 (de) 1999-12-15
IL130160A (en) 2007-07-04
AU5372498A (en) 1998-06-29
CA2273192A1 (en) 1998-06-11
WO1998024923A1 (en) 1998-06-11
IL130160A0 (en) 2000-06-01

Similar Documents

Publication Publication Date Title
EP0676954A4 (de) Hiv-lockvirus.
EP0939589A4 (de) Behandlung und prävention einer hiv-infektion durch gabe von derivaten des humanen chorion-gonadotropins
NO994639L (no) Antimikrobiell forebyggelse og behandling av humant immundeficiensvirus og andre infektiöse sykdommer
CA2271622A1 (en) Antiviral agents from plant extracts and use for treatment of viral infections
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
WO1998001144A2 (en) Antiviral agents from plant extracts and use for treatment of viral infections
ATE181080T1 (de) Hiv-proteaseinhibitoren
SE8602981D0 (sv) Novel medicinal use
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
FI923357A0 (fi) Framstaellning av fettsyramediciner.
EP0853662A4 (de) Neuer replikationsfähiger menschlicher immunschwäche virus typ ii (hiv-2) proviraler klon hiv-2kr
EP0963441A4 (de) Inaktivierung von hiv ko-rezeptoren zur therapie der hiv-infektion
EP0868196A4 (de) Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus
FR2689398B1 (fr) Compositions destinées au traitement de l'infection et des maladies provoquées par le virus de l'hépatite B (HBV).
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
AU3593095A (en) Method of treatment of human immunodeficiency virus (hiv) infection
NO965591D0 (no) Kombinasjonsbehandling av HIV-infeksjon
EP0960216A4 (de) Behandlung von hiv-infektionen durch beeinflussung der interaktion von wirts-topoisomerase mit hiv-gag und rt
EP0316592A3 (de) 3'-Fluor-2',3'-dideoxyuridin und seine therapeutische Verwendung
UA42693C2 (uk) Лікарський засіб для лікування інфекції лентивірусом, препарат для лікування людини, яка інфікована лентивірусом
AP9801368A0 (en) Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection
IT1225262B (it) Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
FR2739560B1 (fr) Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
ZA907348B (en) Method of administering soluble t4 for treatment of human immunodeficiency virus infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020820

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040525